

EXISTING ANTIBODY
pH-DEPENDENT ANTIGEN-BINDING ANTIBODY IN WHICH FcRn BINDING IS ENHANCED IN NEUTRAL pH
ENHANCEMENT OF FcRn BINDING IN NEUTRAL pH
pH-DEPENDENT ANTIGEN-BINDING

Fig. 1



100
10
1
0.1
PLASMA ANTIBODY CONCENTRATION (μg/mL)
0
10
20
30
TIME (DAYS)
Fv4-IgG1 (INTRAVENOUS ADMINISTRATION)
Fv4-IgG1 (SUBCUTANEOUS ADMINISTRATION)
Fv4-IgG1-F1 (INTRAVENOUS ADMINISTRATION)
Fv4-IgG1-F1 (SUBCUTANEOUS ADMINISTRATION)

Fig. 2



hFcγRIa
RU
140
120
100
80
60
40
20
0
-20
Fv4-IgG1-F157
-50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 3



140
120
100
80
60
40
20
0
−20
RU
hFcγRIIa (R)
Fv4-IgG1-F157
−50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 4



hFcγRIIa (H)
Fv4-IgG1-F157
RU
140
120
100
80
60
40
20
0
-20
-50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 5



140
120
100
80
60
40
20
0
−20
RU
hFcγRIIb
↑ Fv4-IgG1-F157
−50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 6



140
120
100
80
60
40
20
0
−20
RU
hFcγRIIIa (F)
Fv4-IgG1-F157
−50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 7



mFcγRI
140
120
100
80
60
40
20
0
-20
RU
↑ Fv4-IgG1-F157
-50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 8



140
120
100
80
60
40
20
0
-20
RU
mFcγRIIb
↑ Fv4-IgG1-F157
-50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 9



140
120
100
80
60
40
20
0
-20
RU
mFcγRIII
↑ Fv4-IgG1-F157
-50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 10



mFcγRIV
↓
140
120
100
80
60
40
20
0
-20
RU
↑ Fv4-IgG1-F157
-50
150
350
550
750
950
1150
TIME (SECONDS)

Fig. 11



140
120
100
80
60
40
20
0
-20
RU
-50
450
950
1450
1950
2450
2950
TIME (SECONDS)
mFcγRIV
mFcγRIIb
mFcγRI
mFcγRIII
Fv4-IgG1-F20

Fig. 12



140
120
100
80
60
40
20
0
-20
RU
-50
450
950
1450
1950
2450
2950
TIME (SECONDS)
mFcγRIIb
mFcγRIV
mFcγRIII
mFcγRI
mPM1-mIgG1-mF3

Fig. 13



100
10
1
0.1
0.01
PLASMA ANTIBODY CONCENTRATION (μg/mL)
0
10
20
30
TIME (DAYS)
Fv4-IgG1-F21
Fv4-IgG1-F140
Fv4-IgG1-F157
Fv4-IgG1-F424

Fig. 14



100
10
1
0.1
PLASMA ANTIBODY CONCENTRATION (μg/mL)
0
10
20
30
TIME (DAYS)
Fv4-IgG1
Fv4-IgG1-F760

Fig. 15



PLASMA ANTIBODY CONCENTRATION (μg/mL)
10
1
0.1
0.01
0
10
20
30
TIME (DAYS)
Fv4-IgG1-F11
Fv4-IgG1-F821
Fv4-IgG1-F890
Fv4-IgG1-F939
Fv4-IgG1-F947
Fv4-IgG1-F1009

Fig. 16



PLASMA ANTIBODY CONCENTRATION (μg/mL)
10
1
0.1
0.01
0
5
10
15
TIME (DAYS)
mPM1-mIgG1-mF40
mPM1-mIgG1-mF38
mPM1-mIgG1-mF39
mPM1-mIgG1-mF14

Fig. 17



RATIO OF BrdU-INCORPORATING CELLS TO CD4-POSITIVE T CELLS (AVERAGE)
1.4%
1.2%
1.0%
0.8%
0.6%
0.4%
0.2%
0.0%
A
B
C
D
E
DONOR
NEGATIVE CONTROL
Fv4-IgG1-F21
Fv4-IgG1-F140

Fig. 18



RATIO OF BrdU-INCORPORATING CELLS TO CD4-POSITIVE T CELLS (AVERAGE)
1.2%
1.0%
0.8%
0.6%
0.4%
0.2%
0.0%
A
B
C
D
E
F
G
H
I
J
DONOR
NEGATIVE CONTROL
hA33-IgG1-F21
hA33-IgG1-F140

Fig. 19



RATIO OF BrdU-INCORPORATING CELLS TO CD4-POSITIVE T CELLS (AVERAGE)
1.2%
1.0%
0.8%
0.6%
0.4%
0.2%
0.0%
A
B
C
D
E
F
G
H
I
DONOR
NEGATIVE CONTROL
hA33-IgG1-F698
hA33-IgG1-F699

Fig. 20



NEGATIVE CONTROL
hA33-IgG1-F698
hA33-IgG1-F763
1.4%
1.2%
1.0%
0.8%
0.6%
0.4%
0.2%
0.0%
RATIO OF BrdU-INCORPORATING CELLS TO CD4-POSITIVE T CELLS (AVERAGE)
A
B
C
D
E
F
G
H
I
J
K
DONOR

FIG. 21



ANTIBODY TITER FOR TEST SUBSTANCE
4500
4000
3500
3000
2500
0
5
10
15
20
25
30
TIME (DAYS)
Fv4-IgG1-F11 #1
Fv4-IgG1-F11 #2
Fv4-IgG1-F11 #3
POSITIVE DETERMINATION STANDARD FOR Fv4-IgG1-F11

Fig. 22




ANTIBODY TITER FOR TEST SUBSTANCE
4000
3500
3000
2500
0
5
10
15
20
25
30
TIME (DAYS)
Fv4-IgG1-F821 #4
Fv4-IgG1-F821 #5
Fv4-IgG1-F821 #6
POSITIVE DETERMINATION STANDARD FOR Fv4-IgG1-F821

Fig. 23

A


ANTIBODY TITER FOR TEST SUBSTANC
50000
40000
30000
20000
10000
0
0
5
10
15
20
25
30
TIME (DAYS)
Fv4-IgG1-F890#1
Fv4-IgG1-F890#2
Fv4-IgG1-F890#3
POSITIVE DETERMINATION STANDARD FOR Fv4-IgG1-F890

B



ANTIBODY TITER FOR TEST SUBSTANC
12000
9000
6000
3000
0
5
10
15
20
25
30
TIME (DAYS)
Fv4-IgG1-F890#1
Fv4-IgG1-F890#2
Fv4-IgG1-F890#3
POSITIVE DETERMINATION STANDARD FOR Fv4-IgG1-F890

Fig. 24



ANTIBODY TITER FOR TEST SUBSTANCE
5000
4000
3000
0
5
10
15
20
25
30
TIME (DAYS)
Fv4-IgG1-F939 #4
Fv4-IgG1-F939 #5
Fv4-IgG1-F939 #6
POSITIVE DETERMINATION STANDARD FOR Fv4-IgG1-F939

Fig. 25



ANTIBODY TITER FOR TEST SUBSTANCE
10000
8000
6000
4000
2000
0
5
10
15
20
25
30
TIME (DAYS)
Fv4-IgG1-F947 #1
Fv4-IgG1-F947 #2
Fv4-IgG1-F947 #3
POSITIVE DETERMINATION STANDARD FOR Fv4-IgG1-F947

Fig. 26



ANTIBODY TITER FOR TEST SUBSTANCE
20000
14000
8000
2000
0
5
10
15
20
25
30
TIME (DAYS)
Fv4-IgG1-F1009 #4
Fv4-IgG1-F1009 #5
Fv4-IgG1-F1009 #6
POSITIVE DETERMINATION STANDARD FOR Fv4-IgG1-F1009

Fig. 27



ANTIBODY TITER FOR TEST SUBSTANCE
130
126
122
10
15
20
25
30
TIME (DAYS)
mPM1-mIgG1-mF14 #1
mPM1-mIgG1-mF14 #2
mPM1-mIgG1-mF14 #3
POSITIVE DETERMINATION STANDARD FOR mPM1-mIgG1-mF14

Fig. 28



ANTIBODY TITER FOR TEST SUBSTANCE
128
126
124
122
120
118
116
10
15
20
25
30
TIME (DAYS)
mPM1-mIgG1-mF39 #4
mPM1-mIgG1-mF39 #5
mPM1-mIgG1-mF39 #6
POSITIVE DETERMINATION STANDARD FOR mPM1-mIgG1-mF39

Fig. 29



ANTIBODY TITER FOR TEST SUBSTANCE
240
220
200
180
160
140
120
100
10
15
20
25
30
TIME (DAYS)
mPM1-mIgG1-mF38 #1
mPM1-mIgG1-mF38 #2
mPM1-mIgG1-mF38 #3
POSITIVE DETERMINATION STANDARD FOR mPM1-mIgG1-mF38

Fig. 30



ANTIBODY TITER FOR TEST SUBSTANCE
134
130
126
122
118
114
10
15
20
25
30
TIME (DAYS)
mPM1-mIgG1-mF40 #4
mPM1-mIgG1-mF40 #5
mPM1-mIgG1-mF40 #6
POSITIVE DETERMINATION STANDARD FOR mPM1-mIgG1-mF40

Fig. 31



10
1
0.1
0.01
PLASMA ANTIBODY CONCENTRATION (μg/mL)
0
2
4
6
8
TIME (DAYS)
Fv4-IgG1-F947
Fv4-IgG1-FA6a/FB4a

Fig. 32



mutation B
mutation A
110
100
90
80
70
60
50
40
30
20
10
0
0 50 100 150 200 250 300 350 400
Fc γ RIIb
Fc γ RIa

Fig. 33



160
140
120
100
80
60
40
20
0
Fc γ RIIa H
mutation B
mutation A
0
50
100
150
200
250
300
350
400
Fc γ RIIb

Fig. 34



180
160
140
120
100
80
60
40
20
0
0
50
100
150
200
250
300
350
400
Fc γ RIIa R
Fc γ RIIb
mutation B
mutation A

Fig. 35



240
220
200
180
160
140
120
100
80
60
40
20
0
0 50 100 150 200 250 300 350 400
FcγRIIIa
FcγRIIb
mutation B
mutation A

Fig. 36



10000
1000
100
10
1
PLASMA HUMAN IL-6R CONCENTRATION (ng/mL)
900
800
700
600
500
400
300
ANTI-HUMAN IL-6R ANTIBODY TITER BY ECL
0
7
14
21
TIME (DAYS)
hsIL-6R CONCENTRATION #1
hsIL-6R CONCENTRATION #2
hsIL-6R CONCENTRATION #3
ANTI-hsIL-6R ANTIBODY TITER #1
ANTI-hsIL-6R ANTIBODY TITER #2
ANTI-hsIL-6R ANTIBODY TITER #3

Fig. 37



PLASMA SOLUBLE HUMAN IL6 RECEPTOR CONCENTRATION (ng/mL)
100
10
1
0
10
20
30
40
TIME (DAYS)
ANTI-MOUSE CD4 ANTIBODY WITHOUT ADMINISTRATION #1
ANTI-MOUSE CD4 ANTIBODY WITHOUT ADMINISTRATION #2
ANTI-MOUSE CD4 ANTIBODY WITHOUT ADMINISTRATION #3
ANTI-MOUSE CD4 ANTIBODY WITHOUT ADMINISTRATION #4
ANTI-MOUSE CD4 ANTIBODY #5
ANTI-MOUSE CD4 ANTIBODY #6
ANTI-MOUSE CD4 ANTIBODY #7
ANTI-MOUSE CD4 ANTIBODY #8

Fig. 38



100
10
1
0.1
0.01
PLASMA ANTIBODY CONCENTRATION (μg/mL)
0
7
14
21
TIME (DAYS)
Fv4-IgG1 #1
Fv4-IgG1 #2
Fv4-IgG1 #3

Fig. 39




hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-v2
hsIL-6R+Fv4-IgG1-F14
hsIL-6R+Fv4-IgG1-F20
hsIL-6R+Fv4-IgG1-F21
hsIL-6R+Fv4-IgG1-F25
hsIL-6R+Fv4-IgG1-F29
hsIL-6R+Fv4-IgG1-F35
hsIL-6R+Fv4-IgG1-F48
hsIL-6R+Fv4-IgG1-F93
hsIL-6R+Fv4-IgG1-F94
hsIL-6R
10000
1000
100
10
1
0
1
2
3
4
TIME (DAYS)
PLASMA SOLUBLE HUMAN IL-6 RECEPTOR CONCENTRATION(ng/mL)

FIG. 40

(i) CRYSTAL STRUCTURE IN THE PRESENCE OF CALCIUM ION



(ii) CRYSTAL STRUCTURE IN THE ABSENCE OF CALCIUM ION




Fig. 41



PLASMA ANTIBODY CONCENTRATION(μg/mL)
10000
1000
100
10
1
0
1
2
3
4
5
6
7
TIME (DAYS)
H54/L28-IgG1
6RL#9-IgG1
FH4-IgG

Fig. 42



PLASMA hsIL-6R CONCENTRATION(ng/mL)
10000
1000
100
10
1
0.0
0.5
1.0
1.5
2.0
TIME (DAYS)
6RL#9-IgG1
FH4-IgG1
hsIL-6R ALONE
H54/L28-IgG1

Fig. 43



1000
100
10
1
PLASMA ANTIBODY CONCENTRATION(μg/mL)
0
1
2
3
4
5
6
7
TIME (DAYS)
6RL#9-N434W
FH4-N434W
H54/L28-N434W

Fig. 44



10000
1000
100
10
1
PLASMA hsIL-6R CONCENTRATION (ng/mL)
0.0
0.5
1.0
1.5
2.0
TIME (DAYS)
6RL#9-N434W
FH4-N434W
hsIL-6R ALONE
H54/L28-N434W

Fig. 45



0.012
0.011
0.010
0.009
0.008
0.007
0.006
0.005
0.004
0.003
0.002
0.001
AU
10.00
12.00
14.00
16.00
18.00
20.00
22.00
24.00
26.00
28.00
30.00
32.00
34.00
MINUTE

FIG. 46



Kabat 1 2
EU index 1-2---------3---------4---------5---------6---------7---------8---------9---------0---------1---------2--
8-0---------0---------0---------0---------0---------0---------0---------0---------0---------0---------0--
IgG1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD-
IgG2 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERK--CC
IgG3 ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLG
IgG4 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG--
Kabat 2
EU index 2---------3---------4---------5---------6---------7---------8
2-----8---------0---------0---------0---------0---------0---------0
IgG1 -KTHTCPP---------CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
IgG2 -V-E-CPP---------CPAPPVA-GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVD
IgG3 DTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVD
IgG4 ---PPCPS---------CPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD
Kabat 2 3
EU index 8---------9---------0---------1---------2---------3---------4---------5---------6---------7---------8-----
1---------0---------0---------0---------0---------0---------0---------0---------0---------0-----
IgG1 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG
IgG2 GVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG
IgG3 GVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSG
IgG4 GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
Kabat 3 4
EU index 8---9---------0---------1---------2---------3---------4
6---0---------0---------0---------0---------0---------0------7
IgG1 QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:11)
IgG2 QPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:12)
IgG3 QPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK (SEQ ID NO:13)
IgG4 QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:14)

FIG. 47

Antigen-binding molecule with enhanced FcRn binding under neutral conditions
Formation of a tetramer complex of one molecule of Fc, two molecules of FcRn, and one molecule of activating FcγR




Fig. 48

(Embodiment 1) Antigen-binding molecule with enhanced FcRn binding under neutral conditions and lowered binding to activating FcγR




Fig. 49

(Embodiment 2) Antigen-binding molecule with enhanced FcRn binding under neutral conditions and selectively-enhanced binding to inhibitory FcγR




Fig. 50

(Embodiment 3)
Antigen-binding molecule in which one side of Fc has enhanced FcRn binding under neutral conditions, and the other does not have FcRn-binding ability under neutral conditions




Fig. 51



L
R
G
D
H
T
N
A
E
S
Y
Library
96
Design
Library
94
Design
Library
93
Design
Library
92
Design
Library
91
Design
Library
53
Design
Library
50
Design
Library
34
Design
Library
30
Design
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Proportion of each amino acid
VL(Kabat numbering)

FIG. 52



Proportion of each amino acid
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Design
Library
30
32
34
50
53
91
92
93
94
96
VL (Kabat numbering)
Y
S
R
N
L
K
H
G
F
D
A

Fig. 53



PLASMA ANTIBODY CONCENTRATION
(μg/mL)
10
1
0.1
0.01
0
2
4
6
8
TIME (DAYS)
Fv4-IgG1-F947
Fv4-IgG1-F1009
Fv4-IgG1-F1326

Fig. 54



BINDING TO FcgRIIaR (F652=100)
800
700
600
500
400
300
200
100
0
F652
0 10 20 30 40 50 60 70 80 90 100 110 120 130
BINDING TO FcgRIIb (F652=100)

Fig. 55



BINDING TO FcgRIIb WHEN EACH ALTERATION DOES NOT COMPRISE P238D
220
200
180
160
140
120
100
80
60
40
20
S239D
G237W
G237F
REGION A
L234Y
L234W
G237D
G237A
G237L
G237Y
G237E
G237M
REGION B
100
105
110
115
120
125
130
135
BINDING TO FcgRIIb WHEN EACH ALTERATION COMPRISES P238D

Fig. 56





FcgRIIb EXTRACELLULAR REGION
Fc CH2 DOMAIN A
Fc CH2 DOMAIN B
Fc CH3 DOMAIN A
Fc CH3 DOMAIN B

Fig. 57



BLACK CRYSTAL STRUCTURE OF Fc(P238D)/FcγRIIb EXTRACELLULAR REGION COMPLEX
GRAY MODEL STRUCTURE OF Fc(WT)/FcγRIIb EXTRACELLULAR REGION COMPLEX

Fig. 58



BLACK CRYSTAL STRUCTURE OF Fc(P238D)/FcγRIIb EXTRACELLULAR REGION COMPLEX

GRAY MODEL STRUCTURE OF Fc(WT)/FcγRIIb EXTRACELLULAR REGION COMPLEX

FIG. 59




Fig. 60



NH1
FcgRIIb
R131
2.8 OD2
3.0
2.8
NH2
2.9
OD1
Fc CH2
DOMAIN B
D270
Fc CH2
DOMAIN B
D238

Fig. 61



600
550
500
450
400
350
300
250
200
150
100
50
BINDING TO FcgRIIaR
B3
IgG1
P238D/P271G
P238D
20
40
60
80
100
120
140
160
BINDING TO FcgRIIb

Fig. 62



FcgRIIb
EXTRACELLULAR
REGION
Fc
Chain A
E233
K113
Fc
Chain B
P238D
P238D

Fig. 63





Fig. 64



BLACK CRYSTAL STRUCTURE OF Fc(P238D)/FcγRIIb EXTRACELLULAR REGION COMPLEX
GRAY CRYSTAL STRUCTURE OF Fc(WT)/FcγRIIIa EXTRACELLULAR REGION COMPLEX (PDB code: 3SGJ)

Fig. 65